RT Journal
A1 Campbell JR
T1 TReatment of acute lead encephalopathy
JF Archives of Pediatrics & Adolescent Medicine
JO Archives of Pediatrics & Adolescent Medicine
YR 1999
FD November 1
VO 153
IS 11
SP 1202
OP 1202
DO 10.1001/archpedi.153.11.1202
UL http://dx.doi.org/10.1001/archpedi.153.11.1202
AB 
I read the article by Gordon et al1 with great interest. I agree that further studies are necessary to assess the safety and efficacy of combinations of chelating agents in humans. In a rat model, Flora et al2 found that the combined regimen of calcium disodium EDTA and meso-2,3 dimercaptosuccinic acid elicited a greater urinary lead elimination and a lower blood lead level than either agent alone. However, the combined regimen was associated with an elevation of the serum transaminase and creatinine levels. Did Gordon et al monitor renal and hepatic functions during the treatment of their patient? If so, were abnormalities noted?